Invesaro

Stocks Health care OGN

NYSE · Health care

Organon & Co. (OGN)

Organon & Co. brought in $6.1B of revenue over the twelve months to June 30, 2026, down 2.5% from a year earlier. Net income was $209M, a net margin of 3.4%. Operating cash flow minus capital spending left $538M of free cash flow in fiscal 2025. At June 30, 2026 it held $1.1B in cash against $8.6B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.

Revenue (last 12 months)
$6.1B
-2.5% year on year
Net margin
3.4%

What Organon & Co. does

Organon & Co. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker OGN.

Revenue and profit by year

Revenue
FY19: $7.8B $7.8B FY19FY21: $6.5B $6.5B FY21FY21: $6.3B $6.3B FY21FY22: $6.2B $6.2B FY22FY23: $6.3B $6.3B FY23FY24: $6.4B $6.4B FY24FY25: $6.2B $6.2B FY25
Net income
FY19: $3.2B $3.2B FY19FY21: $2.2B $2.2B FY21FY21: $1.4B $1.4B FY21FY22: $917M $917M FY22FY23: $1B $1B FY23FY24: $864M $864M FY24FY25: $187M $187M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$6.2Bn/a$187M$0.72$538M
2024$6.4Bn/a$864M$3.33$764M
2023$6.3Bn/a$1B$3.99$548M
2022$6.2Bn/a$917M$3.59$662M
2021$6.3Bn/a$1.4B$5.31$2B
2021$6.5Bn/a$2.2B$8.52$2B

Latest SEC filings

What Organon & Co. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
    Passive stake (5% or more) SCHEDULE 13G
  2. July 31, 2026
    Passive stake changed SCHEDULE 13G/A
  3. July 31, 2026
    Investor disclosure 8-K
  4. July 31, 2026
    Quarterly report 10-Q · period to June 30, 2026
  5. July 23, 2026
    Shareholder vote results 8-K
  6. July 17, 2026
    Additional proxy material DEFA14A
  7. July 17, 2026
    Other event 8-K
  8. June 17, 2026
    Merger proxy statement DEFM14A
  9. June 11, 2026
    Executive or director change 8-K
  10. June 11, 2026
    Additional proxy material DEFA14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 12, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about OGN

What does Organon & Co. do?

Organon & Co. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker OGN.

Is Organon & Co. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $209M on revenue of $6.1B, a net margin of 3.4%.

How much revenue does Organon & Co. make?

Over the twelve months to June 30, 2026 Organon & Co. reported revenue of $6.1B. That is 2.5% less than a year earlier.

When did Organon & Co. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 14, 2026.

Similar companies

JNJ
Johnson & Johnson
LLY
ELI LILLY & Co
MRK
Merck & Co., Inc.
PFE
Pfizer Inc
ABBV
AbbVie Inc.
AZN
Astrazeneca PLC

Follow OGN

Get an email when Organon & Co. files with the SEC: results, executive changes, material agreements and annual reports.

Follow OGN: get an email when it files

Where the numbers come from

Financial figures are the values Organon & Co. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.